https://mindmedicinelaw.com/briefing/dea-corrects-bromazolam-schedule-i-placement-for-clarity-20260624-15971The Psychedelic Journalen2026-06-24T15:06:01.021127+00:00DEA Corrects Bromazolam Schedule I Placement for ClarityDEA, bromazolam, Schedule I, Controlled Substances Act, chemical nomenclature, regulatory clarity, drug policy, legal enforcement, substance classification, psychedelic researchhttps://mindmedicinelaw.com/briefing/dea-schedules-o-desmethyltramadol-as-schedule-i-substance-20260624-15970The Psychedelic Journalen2026-06-24T15:04:41.267993+00:00DEA Schedules O-Desmethyltramadol as Schedule I SubstanceDEA scheduling, O-Desmethyltramadol, Schedule I substances, drug regulation, pharmaceutical industry, psychedelic research, compliance, controlled substances, temporary scheduling, market implicationshttps://mindmedicinelaw.com/briefing/psychedelic-activists-challenge-restrictive-sharing-law-in-u-s-20260623-15946The Psychedelic Journalen2026-06-23T22:03:45.136817+00:00Psychedelic Activists Challenge Restrictive Sharing Law in U.S.psychedelic policy, referendum, drug regulation, community advocacy, psychedelic sharing, grassroots movements, public health, legal challenges, U.S. law, psychedelic researchhttps://mindmedicinelaw.com/briefing/definium-s-lsd-therapy-advances-in-phase-3-depression-trial-20260622-16096The Psychedelic Journalen2026-06-24T15:04:29.960140+00:00Definium's LSD Therapy Advances in Phase 3 Depression TrialLSD therapy, Definium, Phase 3 trial, depression treatment, psychedelic research, regulatory approval, mental health, neuroplasticity, psychoactive effects, clinical trialshttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-depression-treatment-current-insights-20260622-15879The Psychedelic Journalen2026-06-23T22:03:30.970419+00:00Ketamine's Role in Depression Treatment: Current Insightsketamine, depression treatment, treatment-resistant depression, suicidal ideation, NMDA receptor, antidepressant, clinical trials, long-term safety, synaptic plasticityhttps://mindmedicinelaw.com/briefing/opioid-receptor-activation-by-ketamine-and-pcp-implications-20260622-15878The Psychedelic Journalen2026-06-23T22:03:19.253949+00:00Opioid Receptor Activation by Ketamine and PCP: Implicationsketamine, PCP, opioid receptors, NMDAR, therapeutic potential, abuse potential, clinical guidelines, drug development, pharmacology, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/rising-ketamine-use-spurs-safety-concerns-in-the-u-s-20260622-15793The Psychedelic Journalen2026-06-23T15:05:20.100334+00:00Rising Ketamine Use Spurs Safety Concerns in the U.S.ketamine safety, non-clinical ketamine use, ketamine regulation, psychedelic therapy, NMDA receptor antagonist, public health concerns, ketamine misuse, mental health treatment, substance use disorder, regulatory scrutinyhttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-treating-concussion-symptoms-20260622-15630The Psychedelic Journalen2026-06-22T22:04:43.326523+00:00Psilocybin's Potential in Treating Concussion Symptomspsilocybin, concussion treatment, neuroplasticity, psychedelic medicine, clinical trials, neuroinflammation, FDA, EMA, brain injury, public healthhttps://mindmedicinelaw.com/briefing/meditation-s-potential-role-in-psilocybin-therapy-a-new-study-20260622-15469The Psychedelic Journalen2026-06-22T22:04:32.092137+00:00Meditation's Potential Role in Psilocybin Therapy: A New Studypsilocybin therapy, meditation and psychedelics, psychedelic research, mental health treatment, mindfulness practices, clinical trials, neuroplasticity, brain connectivity, therapeutic outcomes, psychedelic therapy protocolshttps://mindmedicinelaw.com/briefing/definium-s-lsd-therapy-advances-in-late-stage-depression-trial-20260622-15629The Psychedelic Journalen2026-06-22T22:04:19.562281+00:00Definium's LSD Therapy Advances in Late-Stage Depression TrialLSD therapy, major depression, psychedelic research, clinical trials, FDA approval, mental health treatment, serotonin receptors, psychedelic-assisted therapy, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/friction-theoretic-framework-new-insights-for-chronic-diseases-20260621-15389The Psychedelic Journalen2026-06-22T22:04:53.128391+00:00Friction-Theoretic Framework: New Insights for Chronic Diseasesfriction-theoretic framework, multi-scale disease progression, treatment-resistant depression, chronic diseases, multi-target therapies, clinical trials, autoimmune diseases, cancer treatment, Metabolic Control Analysis, public health policyhttps://mindmedicinelaw.com/briefing/orexin-receptor-treatment-in-stress-models-new-insights-20260620-15867The Psychedelic Journalen2026-06-23T22:03:54.575245+00:00Orexin Receptor Treatment in Stress Models: New Insightsorexin receptor treatment, neuroplasticity, stress models, anxiety disorders, depression therapy, psychiatric disorders, basolateral amygdala, preclinical research, neurocircuitry, therapeutic approacheshttps://mindmedicinelaw.com/briefing/ineupatorolide-b-s-antidepressant-potential-via-gut-brain-axis-20260620-15395The Psychedelic Journalen2026-06-22T22:05:13.735722+00:00Ineupatorolide B's Antidepressant Potential via Gut-Brain Axisineupatorolide B, antidepressant effects, gut-brain axis, vagus nerve, microbiota-targeted therapy, depression research, preclinical study, mental health treatment, synaptic protein expression, short-chain fatty acidshttps://mindmedicinelaw.com/briefing/ebselen-trial-in-depression-limited-connectivity-changes-20260620-15393The Psychedelic Journalen2026-06-22T22:05:00.775583+00:00Ebselen Trial in Depression: Limited Connectivity Changesebselen, depression treatment, resting-state functional connectivity, clinical trial, brain connectivity, antidepressant adjuncthttps://mindmedicinelaw.com/briefing/colorado-s-new-law-on-ibogaine-access-policy-implications-20260619-16095The Psychedelic Journalen2026-06-24T15:05:51.455687+00:00Colorado's New Law on Ibogaine Access: Policy ImplicationsColorado ibogaine law, psychedelic policy, ibogaine research, psychedelic therapy, legalization of psychedelics, psychedelic safety, 5-MeO-DMT history, psychedelic regulation, mental health treatment, addiction therapyhttps://mindmedicinelaw.com/briefing/canmat-2023-guidelines-on-treatment-resistant-depression-20260619-15070The Psychedelic Journalen2026-06-23T15:05:52.798976+00:00CANMAT 2023 Guidelines on Treatment-Resistant DepressionCANMAT 2023 guidelines, treatment-resistant depression, ketamine, esketamine, psychedelic substances, mental health care, clinical trials, long-term efficacy, pharmacological strategies, non-pharmacological strategieshttps://mindmedicinelaw.com/briefing/cognitive-energy-landscape-insights-from-infancy-to-adolescence-20260619-15026The Psychedelic Journalen2026-06-23T15:05:39.337306+00:00Cognitive Energy Landscape: Insights from Infancy to Adolescencecognitive development, brain maturation, network control theory, diffusion MRI, neurodevelopmental disorders, control energy, cognitive tasks, molecular-level influences, myelination, neurodevelopmental researchhttps://mindmedicinelaw.com/briefing/adaptive-charge-modulation-in-spinal-cord-stimulation-20260618-15074The Psychedelic Journalen2026-06-23T22:04:14.249082+00:00Adaptive Charge Modulation in Spinal Cord Stimulationadaptive charge modulation, spinal cord stimulation, neuromodulation, deep tissue activation, clinical trials, neuroscience, neural interfaces, high-frequency stimulation, regulatory frameworks, chronic stabilityhttps://mindmedicinelaw.com/briefing/bayesian-optimization-enhances-lifu-neuromodulation-precision-20260618-15073The Psychedelic Journalen2026-06-23T22:04:03.826796+00:00Bayesian Optimization Enhances LIFU Neuromodulation PrecisionBayesian optimization, LIFU neuromodulation, BEACUN, functional ultrasound imaging, personalized medicine, clinical trialshttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-proposal-for-ptsd-in-australia-20260618-15046The Psychedelic Journalen2026-06-23T15:06:27.643413+00:00MDMA-Assisted Therapy Proposal for PTSD in AustraliaMDMA therapy, PTSD treatment, Australia healthcare, psychedelic research, public health, clinical trials, psychedelic policy, therapy safety, mental health, international collaborationhttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-cluster-headache-treatment-20260618-15355The Psychedelic Journalen2026-06-23T15:06:10.141782+00:00Psilocybin's Potential in Cluster Headache Treatmentpsilocybin, LSD, cluster headaches, clinical trials, psychedelic research, smoking cessation, quality of life, mental health, testosterone deficiency, public healthhttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-manual-dexterity-neuroscience-insights-20260617-16069The Psychedelic Journalen2026-06-24T15:06:21.385824+00:00Psilocybin's Impact on Manual Dexterity: Neuroscience Insightspsilocybin, manual dexterity, neuroscience, motor skills, clinical trials, therapeutic applications, psychedelic research, motor function, policy implications, safety considerationshttps://mindmedicinelaw.com/briefing/limits-of-pharmacotherapy-in-muscle-dysmorphic-disorder-20260617-15869The Psychedelic Journalen2026-06-24T15:06:11.174005+00:00Limits of Pharmacotherapy in Muscle Dysmorphic Disordermuscle dysmorphic disorder, pharmacotherapy, body dysmorphic disorder, selective serotonin reuptake inhibitors, emerging therapies, psychedelic-assisted therapy, clinical trials, neurobiological mechanisms, treatment efficacy, public health policyhttps://mindmedicinelaw.com/briefing/telehealth-ketamine-therapy-safety-and-feasibility-in-us-study-20260617-15792The Psychedelic Journalen2026-06-23T15:05:06.363286+00:00Telehealth Ketamine Therapy: Safety and Feasibility in US Studytelehealth ketamine therapy, psychedelic treatment, mental health care, remote therapy, depression treatment, anxiety therapy, PTSD treatment, digital health solutions, subcutaneous ketamine, psychedelic research